12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IMGN853: Phase I started

ImmunoGen began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV IMGN853 given on day 1 of a 21-day cycle in about 64 patients with previously treated ovarian cancer, NSCLC or other...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >